moderna

Zika virus vaccine (mRNA-1325 transitioning to mRNA-1893)

Last updated: December 6, 2018

Modality	Program #	Program	Preclinical development	Phase 1	Phase 2	Phase 3 and commercial	Moderna rights
Prophylactic Vaccines – Global health programs	mRNA-1440	Influenza H10N8 vaccine					Worldwide *Advancing subject to funding*
	mRNA-1851	Influenza H7N9 vaccine					Worldwide *Advancing subject to funding*
	mRNA-1325*	Zika vaccine					Worldwide *BARDA funded*
	mRNA-1893	Zika vaccine					Worldwide *BARDA funded*
	mRNA-1388	Chikungunya vaccine					Worldwide *Advancing subject to funding*

Current development efforts are focused on mRNA-1893, which is in IND-enabling GLP toxicology studies

Zika (mRNA-1325 and mRNA-1893)

BARDA remains committed to Zika mRNA vaccine development, under our $125 mm contract

- In Phase I, at three doses up to 100 µg, safety data generated would permit additional dose escalation of mRNA-1325, but we did not yet observe desired immune response at those doses
- Backup candidate, mRNA-1893, uses a different sequence and shows greater efficacy at 1/20th the dose

Species: **NHP**

mRNA-1893 provided complete protection and robust immune response at 20x lower dose than mRNA-1325



Last updated: December 6, 2018

Special note regarding forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s Prospectus filed with the U.S. Securities and Exchange Commission (SEC) on December 7, 2018 and in subsequent filings made by Moderna with SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

moderna